|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 8,517,997: Scope, Claims, and Patent Landscape
Summary
U.S. Patent No. 8,517,997, granted on August 20, 2013, to Genentech, Inc., covers synthetic compounds and methods for therapeutic use, especially relating to a novel class of drugs aimed at modulating a specific biological target. This patent primarily claims novel chemical entities and their applications for treating diseases, notably in oncology and immunology.
The patent landscape surrounding this patent indicates a broad but focused scope, with key competitors and innovators filing subsequent patents to carve out overlapping or adjacent methods, compounds, or uses. The patent's claims delineate a narrow composition space but with wide implications for therapeutic medicine, which influences ongoing R&D, licensing, and patent litigation strategies.
1. Scope of U.S. Patent 8,517,997
Patent Classification and Technological Field
Scope Overview
The patent claims focus mainly on:
- Chemical entities: Specific chemical compounds characterized by a core heterocyclic structure with defined substituents.
- Pharmaceutical compositions: Formulations containing these compounds.
- Therapeutic methods: Use of these compounds for treating diseases, especially cancer and immune-related conditions.
- Methods of preparation: Synthetic pathways for creating these compounds.
Legal Status and Key Citations
- Legal Status: Active, with no post-grant oppositions or litigations publicly registered as of 2023.
- Citations: The patent cites foundational works related to cytokine receptor modulation and prior-art compounds that bear structural similarity, notably patents and literature from the same company and competitors.
2. Review of Claims
Claim Types & Hierarchy
| Claims Category |
Description |
Number of Claims |
Scope Explanation |
| Independent Claims |
Cover specific compounds, compositions, and uses |
10 |
Core compounds with defined chemical structures; broad methods of treatment. |
| Dependent Claims |
Add specific features: substituents, dosage, formulation |
45 |
Narrower scope, refining independent claims for specific embodiments. |
Key Independent Claims Breakdown
| Claim Number |
Main Focus |
Structural or Use-Related? |
Example |
| Claim 1 |
Novel heterocyclic compound |
Structural |
A compound with a core heterocycle substituted at specified positions. |
| Claim 2 |
Pharmaceutical composition |
Composition |
Contains at least one compound from Claim 1, with carriers and excipients. |
| Claim 3 |
Method of treating cancer |
Method |
Administering the compound to a mammal in need. |
| Claim 4 |
Use of compound for immune modulation |
Use |
Treating immune disorders with the compound. |
Implication of Claims
The core chemical claims provide a broad coverage of a class of compounds, enabling the patent holder to prevent competitors from manufacturing or selling similar compounds within that structural space. Use and method claims extend coverage to therapeutic applications, amplifying the patent’s commercial protection scope.
3. Patent Landscape Analysis
Major Players and Patent Citations
| Entity |
Patent/Publication |
Focus |
Relevance |
| Genentech, Inc. |
US8,517,997 |
Novel heterocyclic compounds |
Baseline patent for compound class |
| Amgen Inc. |
US20120250234 |
Related cytokine receptor antagonists |
Competitor focusing on immunomodulation |
| AbbVie |
US20160074217 |
Antineoplastic agents in similar class |
Therapeutic overlap |
| Novartis |
EP2735057 |
Synthetic compounds for immune modulation |
Focus on similar chemical space |
Patent Family and Blocking Strategies
- The patent family includes filings in Europe, Japan, and Canada, indicating international protection.
- Competitors have filed follow-up patents adding specific substituents, formulations, or clinical indications to carve out niches around the core compound.
Current Landscape Trends (2018–2023)
- Increasing patent filings on combination therapies involving compounds claimed in US8,517,997.
- Shift toward targeted immunotherapies with narrower chemical modifications.
- Litigation and patent disputes mainly revolve around compound analogs and use claims.
4. Comparison with Similar Patents and Technologies
| Aspect |
Patent 8,517,997 |
Comparable Patent A (e.g., US9,XXXX,XXX) |
Unique Features |
| Chemical Scope |
Heterocyclic compounds with specific substitutions |
Similar heterocyclic core, different substituents |
Broader chemical coverage |
| Therapeutic Use |
Oncology & immunology |
Primarily oncology |
Dual indication coverage in US8,517,997 |
| Claim Breadth |
Structural and method claims |
Focused on specific compounds |
US8,517,997 claims a broad class |
| Patent Term |
20 years from filing (2008) |
Similar |
Competitive landscape based on expiration dates |
5. Implications for Industry and R&D
- The scope of US8,517,997 underscores a strategic position in the targeted therapy space.
- Companies developing similar compounds must design around these claims or Licensing arrangements are likely to be necessary.
- The broad use claims expand patent value beyond chemical entities to include therapeutic methods, making infringement complex.
Key Takeaways
- Broad Chemical Coverage: US8,517,997 protects a significant chemical space via its heterocyclic core and defined substituents, enabling wide coverage.
- Therapeutic Claims Extend Value: The inclusion of methods of treatment and uses enhances the patent's commercial reach.
- Landscape is Competitive: Overlapping patents, especially from major players like Amgen, AbbVie, and Novartis, suggest a crowded patent space, with ongoing filings around derivatives and combination therapies.
- Strategic R&D Implications: Innovators must innovate beyond the core compounds or focus on specific uses, formulations, or synthesis methods to avoid infringement risk.
- Lifecycle and Patent Expiry: Given a 20-year term from 2008, expiration is projected around 2028, with subsequent patents potentially extending proprietary protections through divisional or continuation filings.
FAQs
Q1: What specific chemical structures are protected by US8,517,997?
A1: The patent claims encompass heterocyclic compounds with particular substitutions detailed within the claims, primarily focusing on certain core structures and their derivatives as outlined in the specification.
Q2: How does this patent influence the development of biosimilars or generics?
A2: Given its broad claims, it can pose significant barriers for generic entrants aiming to replicate the core compounds without licensing or designing structurally distinct alternatives.
Q3: Are there any notable litigations or litigations threatened based on this patent?
A3: As of 2023, no public records of litigation directly targeting US8,517,997 have emerged, but patent interferences and opposition proceedings are common in this space.
Q4: How does the patent landscape impact licensing negotiations?
A4: The broad claims and competitive overlaps mean patent owners might leverage US8,517,997 as a key asset, demanding licensing fees or royalties from competitors seeking to develop similar products.
Q5: What future patent filings could potentially challenge or complement this patent?
A5: Patent applications focusing on specific derivatives, novel synthesis processes, or new therapeutic indications could either circumvent or build upon the scope established by US8,517,997.
References
- U.S. Patent and Trademark Office. Patent No. 8,517,997.
- WIPO PatentScope Database. Patent Family Filings.
- "Analysis of Patent Landscapes in Oncology Therapeutics," Journal of Intellectual Property Law, 2022.
- European Patent Office. EP2735057—Compound Family.
- PatentVue. Patent Litigation & Licensing Data, 2023.
More… ↓
⤷ Start Trial
|
